成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Immunology/Inflammation Anti-infection
  3. STING IFNAR Influenza Virus
  4. Vadimezan

Vadimezan (DMXAA; ASA-404) 是血管破壞劑，是鼠干擾素基因 (STING) 刺激物，也是 I 型 IFN 和其他細(xì)胞因子的強(qiáng)效誘導(dǎo)劑。Vadimezan 具有抗流感病毒 H1N1-PR8 的活性。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Vadimezan Chemical Structure

Vadimezan Chemical Structure

CAS No. : 117570-53-3

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥990
In-stock
5 mg ￥900
In-stock
10 mg ￥1200
In-stock
20 mg ￥2100
In-stock
50 mg ￥4700
In-stock
100 mg 現(xiàn)貨 詢價(jià)
200 mg   詢價(jià)  
500 mg   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

MCE 顧客使用本產(chǎn)品發(fā)表的 45 篇科研文獻(xiàn)

WB
IF

    Vadimezan purchased from MCE. Usage Cited in: J Neuroinflammation. 2023 Apr 30;20(1):101.  [Abstract]

    Vadimezan (DMXAA; 20 mg/kg; i.p.; one dose) inhibits morphine-reduced spinal STING fluorescence intensity in mice.

    Vadimezan purchased from MCE. Usage Cited in: J Neuroinflammation. 2023 Apr 30;20(1):101.  [Abstract]

    Vadimezan (DMXAA; 20 mg/kg; i.p.; daily; two days) significantly upregulates the morphine-induced decreased expression of STING in the spinal dorsal horn of mice.

    Vadimezan purchased from MCE. Usage Cited in: Cell Rep. 2023 Feb 28;42(3):112145.  [Abstract]

    Vadimezan (DMXAA; 50 μM; 4, 6 h) significantly increases the level of IRG1 in RAW264.7 macrophages.

    Vadimezan purchased from MCE. Usage Cited in: Gastroenterology. 2018 May;154(6):1822-1835.e2.  [Abstract]

    Expression of IRF3, p-IRF3, p65 and p-p65 in whole pancreatic extract of acute pancreatitis (AP) mice shown by western blot.

    • 生物活性

    • 實(shí)驗(yàn)參考方法

    • 純度 & 產(chǎn)品資料

    • 參考文獻(xiàn)

    生物活性

    Vadimezan (DMXAA; ASA-404), the tumor vascular disrupting agent (tumor-VDA), is a murine agonist of the stimulator of interferon genes (STING) and also a potent inducer of type I IFNs and other cytokines. Vadimezan has anti-influenza virus H1N1-PR8 activities.

    IC50 & Target

    STING[1], type I IFNs[2]
    細(xì)胞效力
    (Cellular Effect)
    Cell Line Type Value Description References
    A549 IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    Cytotoxicity against human A549 cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    A549 IC50
    207.6 μM
    Compound: 1, DMXAA, Vadimezan
    Indirect cytotoxicity against human A549 cells co-cultured with mouse RAW264.7 cells after 24 hrs by MTT assay
    Indirect cytotoxicity against human A549 cells co-cultured with mouse RAW264.7 cells after 24 hrs by MTT assay
    		[PMID: 24518295]
    A549 IC50
    345 μM
    Compound: 1, DMXAA, Vadimezan
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    Cytotoxicity against human A549 cells after 24 hrs by MTT assay
    		[PMID: 24518295]
    A549 IC50
    91 μM
    Compound: 1, DMXAA, Vadimezan
    Indirect cytotoxicity against human A549 cells co-cultured with human PBMC after 24 hrs by MTT assay
    Indirect cytotoxicity against human A549 cells co-cultured with human PBMC after 24 hrs by MTT assay
    		[PMID: 24518295]
    Bel-7402 IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    BeWo IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human Bewo cells after 48 hrs by MTT assay
    Cytotoxicity against human Bewo cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    BGC-823 IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    Cytotoxicity against human BGC823 cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    BJ CC50
    48.9 μM
    Compound: 1, DMXAA, Vadimezan
    Cytotoxicity against human BJ cells after 24 hrs by MTT assay
    Cytotoxicity against human BJ cells after 24 hrs by MTT assay
    		[PMID: 24518295]
    COLO 320 IC50
    39.5 μM
    Compound: DMXAA
    Antiproliferative activity against human COLO320 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human COLO320 cells after 48 hrs by CCK8 assay
    		[PMID: 28376372]
    H69AR EC50
    > 100 μM
    Compound: 4; DMXAA
    Agonist activity at STING in human THP1 Dual cells assessed as IRF reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay
    Agonist activity at STING in human THP1 Dual cells assessed as IRF reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay
    		[PMID: 35108011]
    H69AR EC50
    > 100 μM
    Compound: 4; DMXAA
    Agonist activity at STING in human THP1-Dual cells assessed as NF-kappaB reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay
    Agonist activity at STING in human THP1-Dual cells assessed as NF-kappaB reporter activation incubated for 20 hrs by quanti-blue SEAP reporter gene assay
    		[PMID: 35108011]
    HeLa IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    Cytotoxicity against human HeLa cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    HepG2 IC50
    100.2 μM
    Compound: DMXAA
    Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human HepG2 cells after 48 hrs by CCK8 assay
    		[PMID: 28376372]
    HepG2 IC50
    100.2 μM
    Compound: DMXAA
    Growth inhibition of human HepG2 cells after 24 hrs by MTT assay
    Growth inhibition of human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 29609121]
    HepG2 IC50
    100.2 μM
    Compound: DMXAA; D
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay
    		[PMID: 29129511]
    HepG2 IC50
    21.25 μM
    Compound: DMXAA; D
    Antiproliferative activity against human HepG2 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay
    Antiproliferative activity against human HepG2 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay
    		[PMID: 29129511]
    HL-60 IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    Cytotoxicity against human HL60 cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    HT-29 IC50
    269.5 μM
    Compound: 1, DMXAA, Vadimezan
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay
    		[PMID: 24518295]
    HUVEC IC50
    > 20 μM
    Compound: 6, Vadimezan
    Cytotoxicity against HUVEC assessed as mitochondrial metabolism after 48 hrs by MTT assay
    Cytotoxicity against HUVEC assessed as mitochondrial metabolism after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    Ishikawa IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human Ishikawa cells after 48 hrs by MTT assay
    Cytotoxicity against human Ishikawa cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    K562 IC50
    19.14 μM
    Compound: DMXAA; D
    Antiproliferative activity against human K562 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay
    Antiproliferative activity against human K562 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay
    		[PMID: 29129511]
    K562 IC50
    57.4 μM
    Compound: DMXAA
    Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human K562 cells after 48 hrs by CCK8 assay
    		[PMID: 28376372]
    K562 IC50
    57.44 μM
    Compound: DMXAA; D
    Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
    Antiproliferative activity against human K562 cells after 24 hrs by MTT assay
    		[PMID: 29129511]
    L02 IC50
    < 100 μM
    Compound: DMXAA
    Cytotoxicity against human HL-7702 cells after 48 hrs by CCK8 assay
    Cytotoxicity against human HL-7702 cells after 48 hrs by CCK8 assay
    		[PMID: 28376372]
    L02 IC50
    < 100 μM
    Compound: DMXAA
    Cytotoxicity against human HL-7702 cells after 48 hrs in presence of DMXAA by CCK8 assay
    Cytotoxicity against human HL-7702 cells after 48 hrs in presence of DMXAA by CCK8 assay
    		[PMID: 28376372]
    L02 IC50
    101.3 μM
    Compound: DMXAA; D
    Antiproliferative activity against human HL-7702 cells after 24 hrs by MTT assay
    Antiproliferative activity against human HL-7702 cells after 24 hrs by MTT assay
    		[PMID: 29129511]
    MCF7 IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    MCF7 IC50
    11.89 μM
    Compound: DMXAA; D
    Antiproliferative activity against human MCF7 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay
    		[PMID: 29129511]
    MCF7 IC50
    54.4 μM
    Compound: DMXAA
    Antiproliferative activity against human MCF7 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human MCF7 cells after 48 hrs by CCK8 assay
    		[PMID: 28376372]
    MCF7 IC50
    54.4 μM
    Compound: DMXAA
    Growth inhibition of human MCF7 cells after 24 hrs by MTT assay
    Growth inhibition of human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 29609121]
    MCF7 IC50
    54.41 μM
    Compound: DMXAA; D
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MCF7 cells after 24 hrs by MTT assay
    		[PMID: 29129511]
    MDA-MB-231 IC50
    12.12 μM
    Compound: DMXAA; D
    Antiproliferative activity against human MDA-MB-231 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells co-treated with pyranoxanthone at 1:1 molar ratio after 24 hrs by MTT assay
    		[PMID: 29129511]
    MDA-MB-231 IC50
    48.4 μM
    Compound: DMXAA
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK8 assay
    Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by CCK8 assay
    		[PMID: 28376372]
    MDA-MB-231 IC50
    48.42 μM
    Compound: DMXAA
    Growth inhibition of human MDA-MB-231 cells after 24 hrs by MTT assay
    Growth inhibition of human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 29609121]
    MDA-MB-231 IC50
    48.44 μM
    Compound: DMXAA; D
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay
    		[PMID: 29129511]
    NIH3T3 IC50
    < 100 μM
    Compound: DMXAA
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by CCK8 assay
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by CCK8 assay
    		[PMID: 28376372]
    NIH3T3 IC50
    < 100 μM
    Compound: DMXAA
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs in presence of DMXAA by CCK8 assay
    Cytotoxicity against mouse NIH/3T3 cells after 48 hrs in presence of DMXAA by CCK8 assay
    		[PMID: 28376372]
    NIH3T3 IC50
    67.8 μM
    Compound: DMXAA; D
    Antiproliferative activity against mouse NIH/3T3 cells after 24 hrs by MTT assay
    Antiproliferative activity against mouse NIH/3T3 cells after 24 hrs by MTT assay
    		[PMID: 29129511]
    SiHa IC50
    > 100 μM
    Compound: 6, Vadimezan
    Cytotoxicity against human SiHa cells after 48 hrs by MTT assay
    Cytotoxicity against human SiHa cells after 48 hrs by MTT assay
    		10.1039/C3MD00372H
    體外研究
    (In Vitro)

    Vadimezan (DMXAA) 是一種血管破壞劑，是干擾素基因刺激因子 (STING) 的鼠類激動(dòng)劑，也是 I 型 IFN 和其他細(xì)胞因子的強(qiáng)效誘導(dǎo)劑。Vadimezan 對(duì) 344SQ-ELuc 細(xì)胞活力沒(méi)有不利影響。研究發(fā)現(xiàn)，Vadimezan 介導(dǎo) NF-κB 通路上調(diào)，表現(xiàn)為 M2 巨噬細(xì)胞中 p65 磷酸化增加[1]。結(jié)果表明，與培養(yǎng)基預(yù)處理的巨噬細(xì)胞相比，Vadimezan 處理的細(xì)胞在所有 MOI 下均免受 VSV 誘導(dǎo)的細(xì)胞毒性。Vadimezan 可有效抑制兩種流感病毒株的生長(zhǎng)，表明 Vadimezan 具有治療耐藥性人類流感病毒株的潛力[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    體內(nèi)研究
    (In Vivo)

    344SQ-ELuc NSCLC 皮下腫瘤對(duì) Vadimezan (DMXAA) 反應(yīng)顯著，注射藥物后生物發(fā)光 (BLI) 信號(hào)明顯減少。Vadimezan 治療 344SQ-ELuc 轉(zhuǎn)移瘤不會(huì)導(dǎo)致光子發(fā)射率下降，治療后腫瘤的組織學(xué)仍與對(duì)照相似。與大型皮下腫瘤一樣，向患有小型皮下腫瘤的小鼠施用 Vadimezan 仍會(huì)導(dǎo)致 6 小時(shí)和 24 小時(shí)光子發(fā)射減少約 2 個(gè)對(duì)數(shù)[1]。Vadimezan 是更有效的 IFN-β mRNA 誘導(dǎo)劑，而 TNF-α mRNA 誘導(dǎo)相對(duì)較弱。Vadimezan 給藥可顯著減少流感感染小鼠的體重減輕[2]。

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Clinical Trial
    分子量

    282.29

    Formula

    C17H14O4
    CAS 號(hào)
    性狀

    固體

    顏色

    White to off-white

    中文名稱

    2,5-己酮可可堿；伐地美生
    運(yùn)輸條件

    Room temperature in continental US; may vary elsewhere.
    儲(chǔ)存方式
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 1 year
    -20°C 6 months
    溶解性數(shù)據(jù)
    細(xì)胞實(shí)驗(yàn)： 

    DMSO 中的溶解度 : 7.14 mg/mL (25.29 mM; 超聲助溶; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

    7.5% sodium bicarbonate 中的溶解度 : 6.67 mg/mL (23.63 mM; 超聲助溶)

    配制儲(chǔ)備液
    濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
    1 mM 3.5425 mL 17.7123 mL 35.4246 mL
    5 mM 0.7085 mL 3.5425 mL 7.0849 mL
    查看完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    • 摩爾計(jì)算器

    • 稀釋計(jì)算器

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質(zhì)量
    =
    濃度
    ×
    體積
    ×
    分子量 *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    濃度 (start)

    C1

    ×
    體積 (start)

    V1

    =
    濃度 (final)

    C2

    ×
    體積 (final)

    V2

    動(dòng)物實(shí)驗(yàn)：

    請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

    以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
    ——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
    以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

    • 方案 一

      請(qǐng)依序添加每種溶劑： 10% DMSO    90% Corn Oil

      Solubility: ≥ 0.71 mg/mL (2.52 mM); 澄清溶液

      此方案可獲得 ≥ 0.71 mg/mL（飽和度未知）的澄清溶液，此方案實(shí)驗(yàn)周期在半個(gè)月以上的動(dòng)物實(shí)驗(yàn)酌情使用。

      以 1 mL 工作液為例，取 100 μL 7.1 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL玉米油中，混合均勻。

    以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

    • 方案 一

      請(qǐng)依序添加每種溶劑： 50% PEG300    50% Saline

      Solubility: 5 mg/mL (17.71 mM); 懸濁液; 超聲助溶

    動(dòng)物溶解方案計(jì)算器
    請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

    給藥劑量

    mg/kg

    動(dòng)物的平均體重

    g

    每只動(dòng)物的給藥體積

    μL

    動(dòng)物數(shù)量

    只
    由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
    請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
    方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
    計(jì)算結(jié)果
    工作液所需濃度 : mg/mL
    儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
    您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
    動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
    連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
    請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
    純度 & 產(chǎn)品資料

    純度: 99.93%

    參考文獻(xiàn)
    Kinase Assay
    [1]

    M2-polarized macrophages are treated with 20 μg/mL Vadimezan (ASA-404) or DMSO vehicle for 30 min. Cells are then lysed and protein denatured in SDS buffer and samples sent for RPPA analysis. Differential abundance of various proteins and/or their phosphorylation status in response to Vadimezan (ASA-404) is assessed[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Cell Assay
    [2]

    RAW 264.7 macrophages are cultured and plated at 1×105 cells/well in a 96-well plate. After overnight incubation at 37°C, cells are treated with medium containing vehicle or Vadimezan (DMXAA) (100 μg/mL). After 6 h, the culture medium is replaced with serum-free DMEM containing VSV at the indicated MOI for 1 h. Cells are then maintained in complete DMEM with 10% FBS. Twenty-four hours later, cells are washed with PBS, fixed with 10% buffered formalin, and rinsed thoroughly with distilled water. Adherent cells are stained with crystal violet[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    Animal Administration
    [1]

    Male 129/Sv mice (6 to 12 week old) are used in this study. To generate subcutaneous tumors, 5×105 344SQ-ELuc cells in 100 μL PBS are injected in both posterior flanks of mice. Tumor growth is monitored every 2 to 4 days via BLI. Once tumors are established (day 10 for systemic metastases; day 7 or day 14 for subcutaneous tumors), mice are given 25 mg/kg of Vadimezan (DMXAA), or DMSO vehicle by i.p. injection. BLI is carried out at 6 and 24 hours [1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.
    參考文獻(xiàn)

    完整儲(chǔ)備液配制表

    * 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
    儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

    可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
    7.5% sodium bicarbonate / DMSO 1 mM 3.5425 mL 17.7123 mL 35.4246 mL 88.5614 mL
    5 mM 0.7085 mL 3.5425 mL 7.0849 mL 17.7123 mL
    10 mM 0.3542 mL 1.7712 mL 3.5425 mL 8.8561 mL
    15 mM 0.2362 mL 1.1808 mL 2.3616 mL 5.9041 mL
    20 mM 0.1771 mL 0.8856 mL 1.7712 mL 4.4281 mL
    DMSO 25 mM 0.1417 mL 0.7085 mL 1.4170 mL 3.5425 mL
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    您最近查看的產(chǎn)品:

    Your information is safe with us. * Required Fields.

       產(chǎn)品名稱：

    		  

    * 需求量：

    * 客戶姓名：

    		 

    * Email：

    * 電話：

    		 

    * 公司或機(jī)構(gòu)名稱：

       留言給我們：

    Bulk Inquiry

    Inquiry Information

    產(chǎn)品名稱：
    Vadimezan
    目錄號(hào)：
    HY-10964
    需求量：